Oral Peptide Delivery Is Finally Producing Usable Bioavailability
Absorption enhancers such as SNAC, and newer small-molecule GLP-1 agonists, are eroding the injection requirement that has defined peptide therapeutics since insulin.
Oral semaglutide demonstrated that a peptide can be delivered enterally with a permeation enhancer, at the cost of bioavailability near 1% and strict fasting requirements.
Higher-dose oral formulations and next-generation enhancers are narrowing that gap, while non-peptide small molecules targeting the same receptors sidestep the problem entirely.
For the research-peptide market, this matters because oral bioavailability claims for compounds like BPC-157 are frequently asserted and rarely supported by human pharmacokinetic data.